CHICAGO -- Patients with extensive-stage small-cell lung cancer (SCLC) lived significantly longer with the addition of cytotoxic agent lurbinectedin (Zepzelca) to maintenance immunotherapy, a large ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...

The September 20, 2009, correspondence by Mispelaere et al, entitled “Reproduction Rates After Cytotoxic Therapy” (J Clin Oncol 27:e118-e119, 2009), was published ...

Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial Autologous MART1-specific CTLs were ...

Rates of acute kidney injury and tubulointerstitial nephritis associated with anticancer therapy have increased worldwide since 2010, attributable mainly to targeted therapies and immunotherapies.

For younger, fit patients with mantle cell lymphoma (MCL), adding the Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib to standard induction therapy with bendamustine/rituximab followed by ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

The concept of adjuvant therapy for cancer was developed at a time when systemic cancer treatment was limited to cytotoxic chemotherapy that could only be administered intermittently but rarely ...

CD19-directed CAR T-cell therapy can lead to sustained remission in DLBCL, but relapse is common, affecting up to 60% of patients. Epcoritamab, a bispecific T-cell engager, may enhance CAR T-cell ...